Skip to main content
SpringerLink
Log in

A Pilot Study on a Muramyltripeptide Lipophilic Derivative Entrapped into Liposomes (CGP 19835A Lipid) in Patients with Advanced Non-Small-Cell Lung Cancer

  • Original Research Article
  • Published:
Drug Investigation Aims and scope Submit manuscript

Summary

The efficacy, tolerability and immunomodulatory effects of CGP 19835A Lipid, a liposomal preparation containing a lipophilic derivative of muramyltripeptide, a drug experimentally known as a potent activator of the macrophage-monocyte system, were evaluated in patients with advanced non-small-cell lung cancer (NSCLC). The immunomodulator was administered intravenously weekly to 12 patients in 3 different dosages: 4mg (n = 4), 2mg (n = 5), and 1mg (n = 3). Adverse events suggesting macrophage activation were observed in almost all patients, despite the dosage used, and included fever, chills, asthenia, anorexia and weight loss. Serum levels of tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), neopterin, C-reactive protein and soluble IL-2 receptors were increased in accordance with clinical side effects. No objective antitumoral effect was observed in patients with bulky NSCLC. When given to these patients, CGP 19835A Lipid appeared to be effective in increasing serum TNF-α levels. This property could be investigated in order to potentiate anticancer chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Calandra T, Gérain J, Heumann O, Baumgartner JD, Glauser MP, et al. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. American Journal of Medicine 91: 23–29, 1991

    Article  PubMed  CAS  Google Scholar 

  • Diehl V, Pfreundschuh M, Steinmetz HT, Schaadt M. Phase I studies of recombinant human tumor necrosis factor in patients with malignant disease. In Bornavida et al. (Eds) Tumor necrosis factor/cachectin and related cytokines, pp. 183–188, Karger, Basel, 1988

    Google Scholar 

  • Engelhardt R, Mackensen A, Galanos C. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Research 51: 2524–2530, 1991

    PubMed  CAS  Google Scholar 

  • Fidler IJ. Systemic activation of macrophages by liposomes containing muramyltripeptide phosphatidylethanolamine for therapy of cancer metastasis. Journal of Liposome Research 1: 451–461, 1990

    Article  Google Scholar 

  • Franchimont P, Reuter A, Gysen P, Bernier J, Vrindts-Gevaert Y. Tumor necrosis factor: un médiateur de la fonction marophagique. Actions biologiques et dosage radioimmunologique. Médecine et Hygiène 45: 2160–2168, 1987

    CAS  Google Scholar 

  • Fredrix EWHM, Wouters EFM, Soeters PB, Vander Aalst ACJM, Kester ADM, et al. Resting energy expenditure in patients with non-small cell lung cancer. Cancer 68: 1616–1621, 1991

    Article  PubMed  CAS  Google Scholar 

  • Girardin E, Grau GE, Dayer JM, Roux-Lombard P, the J5 Study Group, et al. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. New England Journal of Medicine 319: 397–400, 1988

    Article  PubMed  CAS  Google Scholar 

  • Holmes EC. The immunotherapy of lung cancer. In Livingston RB (Ed.) Lung Cancer 1, pp. 51–62, Martins Nijhoff Publishers, The Hague, 1981

    Google Scholar 

  • Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, et al. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. Journal of Clinical Oncology 10: 1310–1316, 1992

    PubMed  CAS  Google Scholar 

  • Kleinerman ES, Murray JL, Snyder JS, Cunningham JE, Fidler IJ. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyltripeptide phosphatidylethanolamine. Cancer Research 49: 4665–4670, 1989

    PubMed  CAS  Google Scholar 

  • Liebes L, Walsh CM, Chachoua A, Oratz R, Richard D, et al. Modulation of monocyte functions by muramyltripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma. Journal of the National Cancer Institute 84: 694–699, 1992

    Article  PubMed  CAS  Google Scholar 

  • Lotze MT. Interleukin-2: basic principles. In De Vita et al. (Eds) Biologic therapy of cancer, pp. 123–141, JB Lippincott Co., Philadelphia, 1991

    Google Scholar 

  • MacEwen EG, Kurzman ID, Rosenthal RC, Smith BW, Manley PA, et al. Therapy of osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyltripeptide. Journal of the National Cancer Institute 81: 935–938, 1989

    Article  PubMed  CAS  Google Scholar 

  • Mattson K, Niiranen A, Pyrhonen S, Farkkila M, Cantell K. Recombinant interferon gamma treatment in non-small cell lung cancer. Antitumour effect and cardiotoxicity. Acta Oncologica 30: 607–610, 1991

    Article  PubMed  CAS  Google Scholar 

  • Moller B, Mogensen SC, Wendelboe P, Bendtzen K, Petersen CM. Bioreactive and inactive forms of tumor necrosis factor - α in spinal fluid from patients with meningitis. Journal of Infectious Diseases 163: 886–889, 1991

    Article  PubMed  CAS  Google Scholar 

  • Murray JL, Kleinermann ES, Cunningham JE, Tatom JR, Andrejcio K, et al. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. Journal of Clinical Oncology 7: 1915–1925, 1989

    PubMed  CAS  Google Scholar 

  • Rubin LA, Kurman CC, Fritz ME, Biddison WE, Goldman ND, et al. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. Journal of Immunology 135: 3172–3177, 1985

    CAS  Google Scholar 

  • Sculier JP, Body JJ. Intravenous administration of amphotericin B entrapped in liposomes: induction of high serum levels of TNF alpha. Annals of Oncology 2: 141–144, 1991

    PubMed  CAS  Google Scholar 

  • Sculier JP, Bron D, Sergysels R, Klastersky J. A pilot study with an ifosfamide, carboplatin and etoposide regimen (ICE) in patients with advanced non-small-cell lung cancer. Drug Investigation 2: 31–37, 1990a

    Article  Google Scholar 

  • Sculier JP, Klastersky J, Libert P, Ravez P, Brohée D, et al. A phase II study evaluating CAVi (cyclophosphamide, adriamycin, vincristin) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small cell lung cancer. Lung Cancer 6: 110–118, 1990b

    Article  Google Scholar 

  • Urba WJ, Hartmann LC, Longo DL, Steis RG, Smith II JW, et al. Phase I and immunomodulatory study of a muramylpeptide, muramyltripeptide phosphatidylethanolamine. Cancer Research 50: 2979–2986, 1990

    PubMed  CAS  Google Scholar 

  • Van Hoogevest P, Eankhauser P. An industrial liposomal dosage form for muramyltripeptide phosphatidylethanolamine (MTP-PE). In Lopez-Berestein et al. (Eds) Liposomes in the therapy of infectious diseases and cancer, pp. 453–466, A.R. Liss, New York, 1989

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Médecine et Laboratoire d’Investigation Clinique H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles, Rue Héger-Bordet, I, B-1000, Brussels, Belgium

    J. P. Sculier, J. Gérain, J. J. Body, E. Markiewicz, P. Mommen, M. Paesmans & J. Klastersky

Authors
  1. J. P. Sculier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Gérain
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. J. Body
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Markiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Mommen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Paesmans
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Klastersky
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sculier, J.P., Gérain, J., Body, J.J. et al. A Pilot Study on a Muramyltripeptide Lipophilic Derivative Entrapped into Liposomes (CGP 19835A Lipid) in Patients with Advanced Non-Small-Cell Lung Cancer. Drug Invest 6, 276–284 (1993). https://doi.org/10.1007/BF03259599

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03259599

Keywords

Search

Navigation